Subject: Fwd: Leerink Partners
From: "paul rowan" <[email-masked]>
To: "Hunter Biden" <[email-masked]>
Date: Tue, 1 Apr 2014 12:26:48 -0400

---------- Forwarded message ----------
From: derrick <[email-masked]>
Date: Tue, Apr 1, 2014 at 12:14 PM
Subject: RE: Leerink Partners
To: Paul <[email-masked]>

http://www.prnewswire.com/news-releases/difusions-cleanfuze-antimicrobial-polymer-receives-european-clearance-247040471.html

Additionally, the standards for CE Mark's changed on March 1st 2014, making
our devices Class III moving forward, hence nobody can follow us for
several years - then they run into our patents.

*From:* Paul [mailto:[email-masked]]
*Sent:* Tuesday, April 01, 2014 11:02 AM

*To:* derrick
*Subject:* Re: Leerink Partners

D:

I will look to call you later today. The company received approval from the
Eiropean FDA to market it's product - correct? Please direct me to where I
can read about the approval. Thx,

PR

Sent from my iPhone

On Apr 1, 2014, at 11:24 AM, "derrick" <[email-masked]> wrote:

We are on a call with Leerink at 1pm EST - open after 2pm.

*From:* paul rowan [mailto:[email-masked] <[email-masked]>]
*Sent:* Tuesday, April 01, 2014 9:10 AM
*To:* derrick
*Subject:* Re: Leerink Partners

we should speak later today if your schedule allows for it

On Tue, Apr 1, 2014 at 9:52 AM, derrick <[email-masked]> wrote:

Yes - but if we take that track we would table any ongoing conversations
with potential acquisition partners and bring in new management.  I can
take the company thru European sales and FDA approval - then we need new
skill sets for growth.

On that track a billion + company can be built from the MITA platform and
existing IP.

*From:* Paul [mailto:[email-masked]]
*Sent:* Tuesday, April 01, 2014 8:48 AM

*To:* derrick
*Subject:* Re: Leerink Partners

Are you willing to raise more than $3mm?

Sent from my iPhone

On Apr 1, 2014, at 9:41 AM, "derrick" <[email-masked]> wrote:

Sell-side representation is basically acting as an intermediate for an
auction process once the 510(k) is in.  Essentially we would have Leerink
press J&J to preempt such a process by paying more...

I am waiting to see the terms on the capital raise - he said "standard
rates" - so I am assuming 5-7%.

*From:* paul rowan [mailto:[email-masked] <[email-masked]>]
*Sent:* Tuesday, April 01, 2014 7:32 AM
*To:* derrick
*Subject:* Re: Leerink Partners

D:

Thanks for your update. Leerink has a solid reputation in the
healthcare/bio space. I am curious about the fees are they charging you for
capital raising. What does "sell-side representation" entail. Please advise.

PR

On Tue, Apr 1, 2014 at 8:05 AM, derrick <[email-masked]> wrote:

Paul,

FYI - we are negotiating with Lance Aldstodt in the NYC office for
sell-side representation.  Once that is completed there will no longer be
an opportunity for non-institutional capital.  The plan is to take J&J
surgeons in Germany, Switzerland, UK and Netherlands (those countries pay
the best of the EU countries) while Leerink leverages an Arthrex offer
(pending) against Depuy Synthes (J&J's orthopedic business).  In tandem we
expect those efforts to drive a very high exit value next March.

This last round of capital will be used towards those ends as well as
additional MITA research and IP filings.

http://www.leerink.com/company/about/

Derrick W. Johns

Founder & CEO

www.difusiontech.com

*Cry 'Havoc,' and let slip the dogs of war**; *

*        -CleanFuze European Approval-CE Mark 12-20-2013*

(512) 284-3338 (m)

fy